Tandem Autologous Transplantation Can Overcome the Poor Prognosis of Double-Hit Multiple Myeloma Patients With 1q21 Gain/Amp and t(4;14)

被引：0
|
作者：
Huang, Beihui [1 ]
Li, Juan [1 ]
Wang, Xiuju [2 ]
Huang, Hongming [3 ]
Xu, Xiaojun [4 ]
Wu, Bingyi [5 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[3] Nantong Univ, Affiliated Hosp, Nantong, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 7, Guangzhou, Guangdong, Peoples R China
[5] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-339
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [31] Synthetic lethality in multiple myeloma harboring double oncogenic hits of 17p13(del) and 1q21(amp)
    Teoh, Phaik Ju
    Chung, Tae-Hoon
    An, Omer
    Chng, Pamela
    Jeyasekharan, Anand
    Yang, He
    Chng, Wee Joo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E50 - E51
  • [32] GAIN/AMPLIFICATION OF 1Q21 IS THE MOST POWERFUL GENETIC PROGNOSTIC FACTOR FOR PATIENTS TREATED BY AUTOLOGOUS STEM CELL TRANSPLANTATION
    Nemec, P.
    Zemanova, Z.
    Michalova, K.
    Tajtlova, J.
    Greslikova, H.
    Filkova, H.
    Zaoralova, R.
    Spicka, I.
    Gregora, E.
    Kralova, D.
    Kupska, R.
    Krejci, M.
    Pour, L.
    Zahradova, L.
    Sandecka, V.
    Adam, Z.
    Kuglik, P.
    Hajek, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 65 - 65
  • [33] Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma
    Avet-Loiseau, H.
    Moreau, P.
    Mathiot, C.
    Charbonnel, C.
    Facon, T.
    Attai, M.
    Hulin, C.
    Marit, G.
    Minvielle, S.
    Harousseau, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] PYGO2-MDR1 Axis in Multiple Myeloma Patients with 1q21 Amplification As Promising Target to Overcome Carfilzomib Resistance
    Iannozzi, Nicolas Thomas
    Garcia, Jessica Burroughs
    Marchica, Valentina
    Franceschi, Valentina
    Toscani, Denise
    Vescovini, Rosanna
    Raimondi, Vincenzo
    Lungu, Oxana
    Todaro, Giannalisa
    Sammarelli, Gabriella
    Scita, Matteo
    Librale, Federica
    Dalla Palma, Anna Benedetta
    Donofrio, Gaetano
    Storti, Paola
    Agnelli, Luca
    Pruneri, Giancarlo
    Giuliani, Nicola
    BLOOD, 2023, 142
  • [35] 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens
    Grzasko, Norbert
    Hus, Marek
    Chocholska, Sylwia
    Pluta, Andrzej
    Hajek, Roman
    Dmoszynska, Anna
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2500 - 2503
  • [36] Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients
    Lim, Kenneth J. C.
    Wellard, Cameron
    Moore, Elizabeth
    Ninkovic, Slavisa
    Chng, Wee Joo
    Spencer, Andrew
    Mollee, Peter
    Hocking, Jay
    Ho, Phoebe Joy
    Janowski, Wojt
    Kim, Kihyun
    Mccaughan, Georgia
    Dun, Karen
    Mcquilten, Zoe K.
    Chen, Fiona
    Quach, Hang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (04): : 243 - 248
  • [37] Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy
    Nemec, Pavel
    Zemanova, Zuzana
    Greslikova, Henrieta
    Michalova, Kyra
    Filkova, Hana
    Tajtlova, Jana
    Kralova, Dana
    Kupska, Renata
    Smetana, Jan
    Krejci, Marta
    Pour, Ludek
    Zahradova, Lenka
    Sandecka, Viera
    Adam, Zdenek
    Buchler, Tomas
    Spicka, Ivan
    Gregora, Evzen
    Kuglik, Petr
    Hajek, Roman
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (04) : 548 - 554
  • [38] Chromosome 1p21 deletion defines a subgroup of multiple myeloma with poor clinical outcomes independent of del(13q), del(p53), t(4;14) or 1q21 amplification
    Chang, Hong
    Qi, Connie
    Jiang, Allan
    Xu, Wei
    Young, Trieu
    Mikhael, Joe
    Trudel, Suzanne
    Chen, Christine
    Reece, Donna
    BLOOD, 2007, 110 (11) : 730A - 730A
  • [39] A Rare Case of Triple-Hit Ultra-High-Risk Multiple Myeloma Harboring t(4;14), t(14;20), and Gain(1q)
    Lu, Jiao
    Wang, Qian
    Wang, Jing
    Zeng, Zhao
    Shi, Xiaolan
    Liu, Dandan
    Chen, Suning
    Yan, Lingzhi
    Fu, Chengcheng
    Pan, Jinlan
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2025,
  • [40] Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade)
    Kuglik, P.
    Zaoralova, R.
    Filkova, H.
    Greslikova, H.
    Nemec, P.
    Oltova, A.
    Pour, L.
    Adam, Z.
    Krejci, M.
    Hajek, R.
    CHROMOSOME RESEARCH, 2007, 15 : 185 - 186
12345